Compare Amgen, Inc. (AMGN) vs Bitdeer Technologies Group (BTDR) Price & Performance

Amgen, Inc.Trade

Bitdeer Technologies GroupTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Bitdeer Technologies Group — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Bitdeer Technologies Group trades at $8.87 (market cap $2.36B). The key difference: Amgen, Inc. is far larger — about 95× Bitdeer Technologies Group's market cap, and Amgen, Inc. pays a 2.43% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.

	AMGN	BTDR
Market Cap	$224.14B	$2.36B
Sector	Health	Technology
52-Week High	$417.20	$25.90
52-Week Low	$271.18	$7.28
Enterprise Value	$267.45B	$3.85B
Dividend Yield	2.43%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

No Aura AI signal available yet.

Bitdeer Technologies Group

BTDR trades at $10.88, up 3.42% today, but remains under bearish technical pressure with recent earnings misses. Revenue grew to $620.25M in 2025, yet net income margin turned negative at -26.96% in 2026. The company secured a significant $4.7B AI data center deal, expanding beyond Bitcoin mining. Analyst consensus is strongly bullish with an 81.82% buy rating and a $22.71 price target, suggesting over 100% upside from current levels.

Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and negative cash flow. Risks include execution on new contracts and persistent earnings volatility. The stock offers speculative upside if operational improvements align with analyst optimism.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

BTDR

Bitdeer Technologies faces uncertainty despite strong revenue growth due to Bitcoin and AI market risks.Seeking Alpha · 22 hours agoNeutral Stocks of INNOVATE Corp. and Bitdeer Technologies plunge over 20% despite positive earnings reports.Danny Green · 1 day agoBearish Bitdeer expands into AI infrastructure with a 16-year renewable energy data center lease in Norway.Tony Dante · 1 day agoNeutral View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.